ACUTE MYELOID LEUKEMIA, REFRACTORY
Clinical trials for ACUTE MYELOID LEUKEMIA, REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA, REFRACTORY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA, REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immune therapy targets tough leukemia in kids and young adults
Disease control Recruiting nowThis early-phase study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are genetically modified to be…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated May 26, 2026 06:56 UTC
-
New hope for young leukemia patients: drug combo targets resistant cancer
Disease control Recruiting nowThis study tests whether adding the drug venetoclax to a standard chemotherapy regimen can help children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. About 40 participants will receive the combination to see if it is safe and eff…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 26, 2026 06:55 UTC
-
New nano drug takes on tough leukemia
Disease control Recruiting nowThis early-phase study tests a new drug called C6 ceramide NanoLiposome (CNL) in 15 adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that …
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Keystone Nano, Inc • Aim: Disease control
Last updated May 26, 2026 06:52 UTC
-
New hope for tough leukemia: daily infusion drug enters human trials
Disease control Recruiting nowThis study tests a new drug called AB8939 in people whose acute myeloid leukemia (AML) has returned or not responded to prior treatments. The main goal is to find a safe dose and see if the drug can shrink or control the cancer. About 78 adults will receive daily infusions, and r…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: AB Science • Aim: Disease control
Last updated May 26, 2026 06:44 UTC
-
New hope for tough blood cancers: ARD103 trial opens
Disease control Recruiting nowThis study tests a new drug called ARD103 in adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 49 participants will rece…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: ARCE Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 06:43 UTC
-
Immune cell combo targets tough leukemia in early trial
Disease control Recruiting nowThis study tests a new treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It combines special immune cells (CIML NK cells) with a drug called atezolizumab. The goal is to find a safe dose and see if the combination can …
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New hope for tough leukemias: experimental drug APL-4098 enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called APL-4098, alone or with standard chemotherapy drugs, in about 100 adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to treatment. The main goals are to check safety, find…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
4,000 leukemia patients to be tracked in massive real-world study
Knowledge-focused Recruiting nowThis study will follow 4,000 people whose acute myeloid leukemia has come back or not responded to treatment. Researchers will collect information on which treatments are used and how long patients live, without giving any new medicine. The goal is to learn what works best in eve…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 26, 2026 06:50 UTC